The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
- PMID: 31481004
- PMCID: PMC7324885
- DOI: 10.2174/1570159X17666190903103923
The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
Abstract
Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood disorders present with treatment-resistant forms of depression, co-morbid anxiety, other psychiatric disorders and bipolar disorders. Standardized essential oils (such as that of Lavender officinalis) have been shown to exert clinical efficacy in treating anxiety disorders. As endocannabinoids are suggested to play an important role in major depression, generalized anxiety and bipolar disorders, Cannabis sativa was suggested for their treatment. The endocannabinoid system is widely distributed throughout the body including the brain, modulating many functions. It is involved in mood and related disorders, and its activity may be modified by exogenous cannabinoids. CB1 and CB2 receptors primarily serve as the binding sites for endocannabinoids as well as for phytocannabinoids, produced by cannabis inflorescences. However, 'cannabis' is not a single compound product but is known for its complicated molecular profile, producing a plethora of phytocannabinoids alongside a vast array of terpenes. Thus, the "entourage effect" is the suggested positive contribution derived from the addition of terpenes to cannabinoids. Here, we review the literature on the effects of cannabinoids and discuss the possibility of enhancing cannabinoid activity on psychiatric symptoms by the addition of terpenes and terpenoids. Possible underlying mechanisms for the anti-depressant and anxiolytic effects are reviewed. These natural products may be an important potential source for new medications for the treatment of mood and anxiety disorders.
Keywords: Cannabidiol; anxiety; depression; entourage; mood disorders; terpenes..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Figures
Similar articles
-
Endocannabinoid system dysfunction in mood and related disorders.Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Epub 2011 Mar 9. Acta Psychiatr Scand. 2011. PMID: 21916860 Review.
-
Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds.J Neuroinflammation. 2023 Mar 19;20(1):77. doi: 10.1186/s12974-023-02734-9. J Neuroinflammation. 2023. PMID: 36935484 Free PMC article. Review.
-
Cannabis Phytomolecule 'Entourage': From Domestication to Medical Use.Trends Plant Sci. 2020 Oct;25(10):976-984. doi: 10.1016/j.tplants.2020.04.007. Epub 2020 May 13. Trends Plant Sci. 2020. PMID: 32417167 Review.
-
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment.Int J Mol Sci. 2021 Jan 14;22(2):778. doi: 10.3390/ijms22020778. Int J Mol Sci. 2021. PMID: 33466734 Free PMC article. Review.
-
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science.Headache. 2018 Jul;58(7):1139-1186. doi: 10.1111/head.13345. Headache. 2018. PMID: 30152161 Review.
Cited by
-
Antidepressant-like Effects of Cannabis sativa L. Extract in an Lipopolysaccharide Model: Modulation of Mast Cell Activation in Deep Cervical Lymph Nodes and Dura Mater.Pharmaceuticals (Basel). 2024 Oct 21;17(10):1409. doi: 10.3390/ph17101409. Pharmaceuticals (Basel). 2024. PMID: 39459047 Free PMC article.
-
Cannabis for Rheumatic Disease Pain: a Review of Current Literature.Curr Rheumatol Rep. 2022 May;24(5):119-131. doi: 10.1007/s11926-022-01065-7. Epub 2022 Apr 29. Curr Rheumatol Rep. 2022. PMID: 35486218 Review.
-
Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.Front Neurosci. 2023 Jun 16;17:1185737. doi: 10.3389/fnins.2023.1185737. eCollection 2023. Front Neurosci. 2023. PMID: 37397463 Free PMC article.
-
Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.Cancers (Basel). 2023 Apr 1;15(7):2119. doi: 10.3390/cancers15072119. Cancers (Basel). 2023. PMID: 37046779 Free PMC article. Review.
-
Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments.Med Chem. 2025;21(5):367-384. doi: 10.2174/0115734064318657240822064240. Med Chem. 2025. PMID: 40525419
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials